La vendita allo scoperto per Streamline Health Solns dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Streamline Health Solns. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Streamline Health Solns (NASDAQ:STRM) Azioni, Report sulle vendite allo scoperto

Streamline Health Solns

Streamline Health Solutions Inc provides transformational data-driven solutions for healthcare organizations. It provides computer software-based solutions through its looking glass platform. Its solutions include coding and CDI, coding audit, and financial management solutions. It offers various services, such as custom integration services, training services, electronic image conversion and database monitoring services. It sells its solutions and services in North America to hospitals and health systems, including physician practices, through its direct sales force and its reseller partnerships.

Streamline Health Solutions, Inc. - Common Stock

Streamline Health Solutions Inc

<h3>Gainers</h3>
<ul>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) shares rose 187.3% to $0.75 during Tuesday's pre-market session. The company's market cap stands at $11.6 million. The company's, Q4 earnings came out yesterday. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares moved upwards by 137.3% to $0.86. The market value of their outstanding shares is at $2.8 million. </li>
<li>Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) shares moved upwards by 42.46% to $67.0. The company's market cap stands at $364.2 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>Gain Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) stock increased by 27.1% to $2.43. The market value of their outstanding shares is at $64.3 million. As per the press release, Q4 earnings came out 3 days ago. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares moved upwards by 25.08% to $0.04. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares moved upwards by 24.13% to $1.08. The market value of their outstanding shares is at $12.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Performant Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHLT#NASDAQ">PHLT</a>) stock declined by 52.7% to $1.4 during Tuesday's pre-market session. The company's market cap stands at $109.6 million. </li>
<li>InnovAge Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) shares decreased by 19.13% to $2.41. The market value of their outstanding shares is at $325.9 million. </li>
<li>Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) shares fell 18.22% to $2.29. The market value of their outstanding shares is at $9.7 million. </li>
<li>OncoCyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCX#NASDAQ">OCX</a>) shares decreased by 17.98% to $2.51. The market value of their outstanding shares is at $71.7 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares declined by 17.84% to $0.76. The company's market cap stands at $54.6 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) stock fell 9.14% to $0.36. The market value of their outstanding shares is at $9.0 million. As per the news, the Q4 earnings report came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BIAF

CTOR

GANX

INNV

NUTX

PHLT

RSLS

SNSE

STRM

STSS

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

News

Streamline Health Signed A New Contract For The Use Of RevID With A 120-bed, Oracle Health-ehr Based Health System With Facilities In Kentucky

Contracts

Streamline Health Signs New Contract For Use Of eValuator With Deaconess Health System

Streamline Health Solutions Announced That It Has Signed A New Contract For The Use Of RevID With A 400-bed, Oracle Health-EHR Based Health System With Facilities In Western Texas

Due to the continued unpredictability of timing related to the closing of new contracts, the Company has not provided more specific guidance related to the timing of bookings.

Guidance

Streamline Health Reiterates $15.5M Implemented SaaS ARR Adjusted EBITDA Breakeven Run Rate Expectation; Accelerates Expectation For Achievement The Goal To H1 Of FY25

Earnings

Streamline Health Q3 EPS $(0.61) Up From $(3.15) YoY, Sales $4.42M Down From $6.13M YoY

<h3>Companies Reporting Before The Bell</h3>
• Zedge (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ZDGE#AMEX">ZDGE</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $7.28 million. 
<h3>Companies Reporting After The Bell</h3>
• Quipt Home Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QIPT#NASDAQ">QIPT</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $65.75 million. 
• Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $5.31 million. 
• Red Cat Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) is expected to report quarterly loss at $0.09 per share on revenue of $4.13 million. 
• Mitek Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MITK#NASDAQ">MITK</a>) is expected to report quarterly earnings at $0.17 per share on revenue of $41.30 million. 
• RCI Hospitality Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RICK#NASDAQ">RICK</a>) is projected to report quarterly earnings at $0.37 per share on revenue of $72.98 million. 
• Ark Restaurants (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARKR#NASDAQ">ARKR</a>) is estimated to report earnings for its fourth quarter. 
• Mama`s Creations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAMA#NASDAQ">MAMA</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $30.05 million. 
• Compass Minerals Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>) is likely to report quarterly loss at $0.52 per share on revenue of $208.68 million. 
• Ocean Power Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#AMEX">OPTT</a>) is projected to report earnings for its second quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARKR

MAMA

MITK

OPTT

QIPT

RCAT

RICK

ZDGE

Earnings Scheduled For December 16, 2024

Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) is preparing to release its quarterly earnings on Monday, 2024-12-16. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Streamline Health Solns to report an earnings per share (EPS) of $-0.03.
Streamline Health Solns bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $0.15, leading to a 48.39% drop in the share price on the subsequent day.
Here's a look at Streamline Health Solns's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.60</td>
<td>-0.60</td>
<td>-0.6</td>
<td>-0.6</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.75</td>
<td>-0.75</td>
<td>-0.3</td>
<td>-0.3</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-48.0%</td>
<td>-20.0%</td>
<td>-4.0%</td>
<td>7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1734098458_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Streamline Health Solns were trading at $3.42 as of December 10. Over the last 52-week period, shares are down 35.59%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/STRM/earnings">To track all earnings releases for Streamline Health Solns visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For Streamline Health Solns

<h3>Gainers</h3>
<ul>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock rose 110.0% to $4.41 during Monday's pre-market session. The company's market cap stands at $3.6 million. </li>
<li>Metagenomi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGX#NASDAQ">MGX</a>) stock rose 34.05% to $2.48. The market value of their outstanding shares is at $92.8 million. </li>
<li>Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) shares increased by 25.17% to $1.84. The company's market cap stands at $148.9 million. </li>
<li>CervoMed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) shares increased by 20.82% to $14.39. The company's market cap stands at $118.7 million. </li>
<li>Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) shares moved upwards by 16.71% to $3.77. The market value of their outstanding shares is at $15.9 million. </li>
<li>Kodiak Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) shares increased by 14.22% to $8.94. The company's market cap stands at $470.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bioage Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOA#NASDAQ">BIOA</a>) stock decreased by 72.1% to $5.6 during Monday's pre-market session. The company's market cap stands at $200.7 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares fell 51.33% to $1.65. The company's market cap stands at $2.6 million. </li>
<li>Radiopharm Theranostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>) shares fell 40.22% to $11.3. The company's market cap stands at $24.5 billion. </li>
<li>Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) shares decreased by 20.69% to $3.03. The company's market cap stands at $317.8 million. </li>
<li>Invizyne Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IZTC#NASDAQ">IZTC</a>) shares fell 18.36% to $10.81. The market value of their outstanding shares is at $103.0 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock declined by 16.46% to $1.98. The market value of their outstanding shares is at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIOA

CRVO

IPHA

IZTC

RADX

RVNC

SONN

12 Health Care Stocks Moving In Monday's Pre-Market Session

WIIM

Streamline Health Solutions shares are trading higher after the company announced it signed a new contract.

Streamline Health Signs New Contract For Use Of eValuator With 900-Bed, Altera EHR-Based Health System Serving Northern Texas

Streamline Health Solutions Announced That It Has Expanded Its Relationship With An Existing eValuator Client Include The Recently Released eValuator Quality Module

<h3>Gainers</h3>
<ul>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock moved upwards by 55.3% to $1.91 during Wednesday's regular session. The company's market cap stands at $3.5 million. </li>
<li>Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) stock rose 24.54% to $2.74. The company's market cap stands at $11.5 million. </li>
<li>Inhibikase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) shares moved upwards by 22.68% to $1.46. The market value of their outstanding shares is at $10.8 million. </li>
<li>Kezar Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZR#NASDAQ">KZR</a>) stock moved upwards by 18.28% to $0.88. The company's market cap stands at $63.8 million. </li>
<li>Shattuck Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>) shares rose 15.88% to $1.46. The company's market cap stands at $69.6 million. </li>
<li>CASI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASI#NASDAQ">CASI</a>) stock moved upwards by 15.78% to $6.6. The market value of their outstanding shares is at $102.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock decreased by 22.0% to $0.72 during Wednesday's regular session. The company's market cap stands at $1.1 million. </li>
<li>Ontrak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) shares declined by 21.52% to $2.17. The company's market cap stands at $6.9 million. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) stock fell 16.32% to $1.21. The market value of their outstanding shares is at $47.6 million. </li>
<li>Regional Health Props (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RHE#AMEX">RHE</a>) stock decreased by 14.09% to $2.13. The market value of their outstanding shares is at $4.0 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock decreased by 13.64% to $0.23. The company's market cap stands at $1.3 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock declined by 11.72% to $0.1. The company's market cap stands at $1.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEON

CASI

NUWE

OTRK

STTK

TIVC

WINT

12 Health Care Stocks Moving In Wednesday's Intraday Session

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

<h3>Gainers</h3>
<ul>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) shares rose 77.0% to $5.94 during Friday's pre-market session. The company's market cap stands at $4.4 million. </li>
<li>Establishment Labs Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESTA#NASDAQ">ESTA</a>) stock moved upwards by 28.6% to $52.98. The market value of their outstanding shares is at $1.4 billion. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) stock rose 17.89% to $0.29. The market value of their outstanding shares is at $7.0 million. </li>
<li>LakeShore Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSB#NASDAQ">LSB</a>) stock rose 10.25% to $0.86. The market value of their outstanding shares is at $161.5 million. </li>
<li>Certara (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>) stock increased by 9.77% to $11.75. The market value of their outstanding shares is at $1.8 billion. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares increased by 9.56% to $0.3. The market value of their outstanding shares is at $2.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares fell 18.6% to $1.66 during Friday's pre-market session. The company's market cap stands at $2.2 million. </li>
<li>enVVeno Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) shares decreased by 17.12% to $3.73. The market value of their outstanding shares is at $49.7 million. </li>
<li>Aytu BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYTU#NASDAQ">AYTU</a>) stock fell 16.11% to $2.39. The company's market cap stands at $14.2 million. The company's, Q4 earnings came out yesterday. </li>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) shares declined by 14.29% to $3.42. The market value of their outstanding shares is at $6.0 million. </li>
<li>Cassava Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) shares declined by 10.53% to $28.51. The company's market cap stands at $1.3 billion. </li>
<li>Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) shares fell 10.35% to $0.21. The market value of their outstanding shares is at $13.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AYTU

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

CERT

ENSC

ESTA

NVNO

ONCO

SAVA

TBIO

TOVX

12 Health Care Stocks Moving In Friday's Pre-Market Session

The 1-for-15 ratio is within the range approved by the Company&#39;s stockholders at the Special Meeting of Stockholders held on September 19, 2024.

Stock Split

Streamline Health Plans To Proceed With 1-For-15 Reverse Stock Split Of Its Outstanding Shares Of Common Stock

<h3>Gainers</h3>
<ul>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) stock increased by 16.8% to $0.29 during Thursday's after-market session. The company's market cap stands at $6.9 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) stock rose 6.69% to $6.16. The market value of their outstanding shares is at $3.1 million. </li>
<li>Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) shares moved upwards by 6.01% to $0.88. The company's market cap stands at $134.0 million. </li>
<li>Chromocell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#AMEX">CHRO</a>) shares moved upwards by 5.88% to $1.08. The company's market cap stands at $6.2 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock moved upwards by 5.4% to $1.17. The company's market cap stands at $7.1 million. </li>
<li>China Pharma Holdings, Inc. Common Stock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) stock rose 5.2% to $0.26. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) shares decreased by 27.8% to $0.33 during Thursday's after-market session. The company's market cap stands at $15.9 million. </li>
<li>enVVeno Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) stock declined by 15.34% to $3.81. The market value of their outstanding shares is at $50.7 million. </li>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) stock decreased by 7.04% to $3.7. The market value of their outstanding shares is at $6.5 million. </li>
<li>Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) shares declined by 6.17% to $0.21. The company's market cap stands at $13.3 million. </li>
<li>Lipella Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) stock fell 5.38% to $0.48. The market value of their outstanding shares is at $3.8 million. </li>
<li>Travere Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) shares declined by 5.12% to $14.27. The market value of their outstanding shares is at $1.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIVI

CHRO

CPHI

LIPO

MCRB

TCBP

TVTX

12 Health Care Stocks Moving In Thursday's After-Market Session

Streamline Health Solutions shares are trading lower after the ocmpany reported mixed Q2 financial results.

The Company reiterated that it believes its adjusted EBITDA breakeven run rate is&nbsp;$15.5 million&nbsp;of implemented SaaS ARR, but due to the aforementioned client non-renewals, the Company has revised its expected timeline to achieve this run rate from the second half of fiscal 2024 to the second half of fiscal 2025.

Streamline Health Revises Expected Timeline To Achieve SaaS ARR Adjusted EBITDA Breakeven Run Rate From H2 Of FY24 To H2 Of FY25

Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. This is a 25 percent decrease over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $4.48 million which beat the analyst consensus estimate of $4.33 million by 3.25 percent. This is a 22.43 percent decrease over sales of $5.77 million the same period last year.

Earnings Beats

Earnings Misses

Streamline Health Solns Q2 2024 GAAP EPS $(0.05) Misses $(0.04) Estimate, Sales $4.48M Beat $4.33M Estimate

Press Releases

Streamline Health® Announces 1-For-15 Reverse Stock Split

Streamline Health® Debuts eValuator™ Quality Module

Streamline Health® Adds Quality Module to Existing eValuator Relationship

Streamline Health® Adds Quality Module to Third eValuator™ Client

Streamline Health® Announces New eValuator™ Contract With Texas-Based Health System

Streamline Health® To Report Fiscal Third Quarter 2024 Financial Performance

Streamline Health® Reports Fiscal Third Quarter 2024 Financial Results, Accelerates Anticipated Adjusted EBITDA Breakeven Timeline

Streamline Health® Expands Presence In Texas with 400-Bed Health System for RevID

Streamline Health® Announces New eValuator™ Contract with Deaconess Health System

Streamline Health® Announces Fourth CommunityWorks RevID Contract With Kentucky-Based Health System

Comments

Streamline Health Solns

Vendite allo scoperto

Streamline Health Solns (NASDAQ:STRM) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO